Aim: detection of hyper-α-amylasemia in radically operated patients with gastric cancer, according to the conservative treatment recieved. Material and Methods: The retrospective study group of 101 patients with gastric cancer, who underwent radical surgery and manifested acute pancreatitis during the postoperative period. The first subgroup (typical surgeries) consisted of 40 patients, the second subgroup (expanded and combined surgeries) - 61 patients. The prospective group composed of 34 patients with gastric cancer after radical surgery received Sandostatine 0,1 mg for prophylactic reason. Results: The incidence of postoperative acute pancreatitis is increased in gastrectomy (57,69%) compared with gastric resection (33,33%), having the highest rate in excision of gastric stump (100%), while mortality caused by pancreonecrosis remains at an almost constant rate (2,5% to 4%). The average duration of hyper-α-amylasemia depends on the type of the treatment and represents 2-7 days for patients treated with Contrical only and 2-4 days for patients who received Sandostatine as well. In 17 patients the hyper-α-amylasemia lasted between 8 and 11 days (because of the onset of pancreonecrosis), which is explained by the delayed initiation of treatment with Sandostatine, only from the 4-th day of the postoperative period. 22 patients from the prospective group received Sandostatine 0,1 mg intraoperative and in 15 (68,18%) cases hyper-α-amylasemia was not detected. Other 12 patients from the same group recieved Sandostatine 0,1 mg in the first postoperative day and only in 3 (25%) cases hyper-α-amylasemia was not detected. Conclusion: The number of cases with postoperative acute pancreatitis have decreased due to intraoperative administration of Sandostatine 0,1 mg.